Denali Therapeutics (DNLI) Return on Capital Employed (2018 - 2024)
Historic Return on Capital Employed for Denali Therapeutics (DNLI) over the last 7 years, with Q4 2024 value amounting to 0.37%.
- Denali Therapeutics' Return on Capital Employed fell 2000.0% to 0.37% in Q4 2024 from the same period last year, while for Dec 2024 it was 0.37%, marking a year-over-year decrease of 2000.0%. This contributed to the annual value of 0.42% for FY2024, which is 2600.0% down from last year.
- Latest data reveals that Denali Therapeutics reported Return on Capital Employed of 0.37% as of Q4 2024, which was down 2000.0% from 0.35% recorded in Q3 2024.
- Denali Therapeutics' Return on Capital Employed's 5-year high stood at 0.05% during Q4 2020, with a 5-year trough of 0.4% in Q1 2020.
- Its 5-year average for Return on Capital Employed is 0.23%, with a median of 0.29% in 2022.
- As far as peak fluctuations go, Denali Therapeutics' Return on Capital Employed skyrocketed by 4500bps in 2020, and later tumbled by -3700bps in 2022.
- Quarter analysis of 5 years shows Denali Therapeutics' Return on Capital Employed stood at 0.05% in 2020, then crashed by -669bps to 0.28% in 2021, then decreased by -23bps to 0.35% in 2022, then skyrocketed by 49bps to 0.18% in 2023, then crashed by -111bps to 0.37% in 2024.
- Its last three reported values are 0.37% in Q4 2024, 0.35% for Q3 2024, and 0.33% during Q2 2024.